Blackfynn announced that its is acquiring the rights to a candidate Parkinson’s disease treatment that others gave up on but is thought ready to move into pivotal Phase 3 testing. Neither the investigative treatment nor the company that initially developed it — or other details of this acquisition — were identified in a Blackfynn press release. “We are excited to apply Blackfynn’s approach, first to the development of this promising lead candidate for Parkinson’s, and then systematically…

You must be logged in to read/download the full post.